Coumadin and Posterior capsule opacification - a phase IV clinical study of FDA data

Summary:

Posterior capsule opacification is reported as a side effect among people who take Coumadin (warfarin sodium), especially for people who are male, 60+ old, also take Aredia, and have Hypercalcaemia.

The phase IV clinical study analyzes which people have Posterior capsule opacification when taking Coumadin. It is created by eHealthMe based on reports of 128,882 people who have side effects when taking Coumadin from the FDA, and is updated regularly.

What is Coumadin?

Coumadin has active ingredients of warfarin sodium. It is often used in blood clots. eHealthMe is studying from 133,228 Coumadin users. Check the latest studies of Coumadin.

What is Posterior capsule opacification?

Posterior capsule opacification is found to be associated with 138 drugs and 143 conditions by eHealthMe. Check the latest studies of Posterior capsule opacification.

On Jul, 19, 2026

128,882 people reported to have side effects when taking Coumadin.
Among them, 32 people (0.02%) have Posterior capsule opacification.

Could Coumadin cause Posterior capsule opacification?

Among these 32 people:

What is the gender of people who have Posterior capsule opacification when taking Coumadin? *

female: 0.0 %
male: 100 %

What is the age of people who have Posterior capsule opacification when taking Coumadin? *

What are other drugs people take besides Coumadin? *

What are other side effects people have besides Posterior capsule opacification? *

Cataract (clouding of the lens inside the eye): 30 people, 93.75%
Pain: 29 people, 90.62%
Injury: 28 people, 87.50%
Type 2 Diabetes: 25 people, 78.12%
Actinomycosis (infection that causes sores, or abscesses): 23 people, 71.88%
Osteonecrosis Of Jaw (death of bone of jaw): 23 people, 71.88%
Osteomyelitis (infection of bone): 22 people, 68.75%
Primary Sequestrum (piece of dead bone that has become separated during the process of necrosis from normal/sound bone): 20 people, 62.50%
Dental Fistula: 18 people, 56.25%
Jaw Disorder (jaw disease): 18 people, 56.25%

What are the existing conditions these people have? *

Hypercalcaemia (elevated calcium (ca+) level in the blood): 18 people, 56.25%
Multiple Myeloma (cancer of the plasma cells): 17 people, 53.12%
Pain: 12 people, 37.50%
Metastases To Bone (cancer spreads to bone): 12 people, 37.50%
Bone Loss: 11 people, 34.38%
Osteoporosis (bones weak and more likely to break): 11 people, 34.38%
Anaemia (lack of blood): 6 people, 18.75%
Neuropathy Peripheral (surface nerve damage): 6 people, 18.75%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 2 people, 6.25%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Coumadin and have Posterior capsule opacification?

- Check whether Posterior capsule opacification is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Coumadin:

Coumadin (133,228 reports)

Browse all side effects of Coumadin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Posterior capsule opacification:

Posterior capsule opacification (138 drugs)

Browse all the conditions that are associated with Posterior capsule opacification:

Posterior capsule opacification (143 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on warfarin sodium (the active ingredients of Coumadin) and Coumadin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.